Currently, the treatment recommendations are for patients with KRAS-mutant NSCLC to receive standard-of-care chemotherapy or, if eligible, to participate in a clinical trial (Sequist & Neal, 2015). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.